Genequantum And Biomap Collaborate For Next-gen Adc Therapeutics

By Author: Ben Gross
Total Articles: 433
Comment this article

GeneQuantum Healthcare (GQ) and BioMap have entered a strategic collaboration to co-develop FIC/BIC ADC therapeutics, focusing on ADC new drug development and innovative bioconjugation technologies. GQ's enzymatic site-specific conjugation technology and linker-payload platform will merge with BioMap's life science AI Foundation, including the trillion-parameter Large Language Model xTrimo and AI protein generation platform AIGP. The collaboration aims to create novel ADCs addressing high unmet medical needs by leveraging GQ's expertise in ADC drug development and BioMap's capabilities in target recommendation, high-performance antibody design, and AI-driven solutions. The partnership seeks to enhance R&D efficiency, reduce development costs, and accelerate the development of breakthrough ADC therapeutics, contributing to a new paradigm in global ADC drug development.

Dr. Gang Qin, Founder and Chairman of GQ, expressed the shared commitment to disruptive innovation, emphasizing collaborative synergy to address global medical needs. Vicky Qu, Senior VP of BioMap, highlighted their Foundation Model's potential and the goal to improve ADC drug safety and efficacy through precise disease selection. The collaboration reflects a strategic approach to advance ADC drug development by integrating each partner's strengths and fostering generative capabilities in life science R&D scenarios.

More Information : https://www.techdogs.com/tech-news/pr-newswire/genequantum-and-biomap-establish-a-strategic-collaboration-to-jointly-develop-a-series-of-next-generation-adc-therapeutics